Beyond KRAS, patients with KRAS G12C-mutated colorectal cancers were most commonly characterized by alterations including both point mutations and amplifications of NRAS, BRAF, MAP2K1, and EGFR, ...
patients with KRAS G12C-mutated colorectal cancers were most commonly characterized by alterations including both point mutations and amplifications of NRAS, BRAF, MAP2K1, and EGFR, whereas MYC ...
Accordingly, the researchers next plan to investigate the extent to which individual KRAS mutations influence response to EGFR inhibitors, such as cetuximab. “Future personalized patient ...
patients with KRAS G12C-mutated colorectal cancers were most commonly characterized by alterations including both point mutations and amplifications of NRAS, BRAF, MAP2K1, and EGFR, whereas MYC ...
The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC ...
(A) Oncogene mutations were grouped together when they occurred within a given gene (e.g., 'KRAS' for all mutations ... the mutation was grouped separately (e.g., 'EGFR_T790M' for the T790M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback